# INDERIDE LA 80/50

Product · id `cardio:fdaprod-nda019059` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [openFDA record NDA019059](<https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA019059>), retrieved 8 November 2026. No person wrote or checked this page.

Browse, organ or system: Heart; Kidneys  
Browse, condition area: High blood pressure; Coronary and vascular disease; Heart rhythm problems; Heart failure  

## In plain language

A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 3 brand names.

## Technical summary

Drugs@FDA application NDA019059. Original approval 1985-07-03. No efficacy supplement approvals are on record. 3 products listed.

## The registry's words

- Application: NDA019059
- Brand name: INDERIDE LA 160/50
- Brand name: INDERIDE LA 80/50
- Brand name: INDERIDE LA 120/50
- Applicant: WYETH AYERST
- Active ingredient: HYDROCHLOROTHIAZIDE
- Active ingredient: PROPRANOLOL HYDROCHLORIDE
- Dosage form: CAPSULE, EXTENDED RELEASE
- Route: ORAL

## Claims, with the population each applies to

## Context: FDA record read by the openFDA feed

Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)

### FDA records an approval of NDA019059 on 1985-07-03.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application NDA019059 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA019059>
     Locator: submissions\[4\].submission\_status\_date. Retrieved 2026-11-08T20:51:56Z. Source state: Current. Version fingerprint: 858da4519bee9513ab48f56f74e565bd2cdda86efacb7d743809b5913a51fc27.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application NDA019059 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA019059>
     Locator: application\_number. Retrieved 2026-11-08T20:51:56Z. Source state: Current. Version fingerprint: 858da4519bee9513ab48f56f74e565bd2cdda86efacb7d743809b5913a51fc27.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application NDA019059 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA019059>
     Locator: submissions\[4\].submission\_status. Retrieved 2026-11-08T20:51:56Z. Source state: Current. Version fingerprint: 858da4519bee9513ab48f56f74e565bd2cdda86efacb7d743809b5913a51fc27.
     How it applies: The decision status as the record writes it.

## Guidance, authorization and access

### Regulatory decision `cardio:fdadec-nda019059-approval`

- Product: INDERIDE LA 80/50 (`cardio:fdaprod-nda019059`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Approval, 1985-07-03
- Product version: Original application
- Pathway: NDA
- Submission: NDA019059
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-nda019059-approval`

## Connected pages

- Registry active ingredient is this drug: Hydrochlorothiazide (`cardio:hydrochlorothiazide`)
- Registry active ingredient is this drug: Propranolol (`cardio:propranolol`)

## Provenance

Content hash: c8e04b5a410c8d649b8a96c29e803b55a92219a73e2c66677021825b06770990
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
